ArticleInternational journal of nanomedicine2020
Gold Nanoparticles Mediated Drug-Gene Combinational Therapy for Breast Cancer Treatment.
Article in International journal of nanomedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 58 citations in OpenAlex.
- Carrier-free self-assembled nanoparticles derived from traditional Chinese medicine active components: construction strategies and applications.RSC advances · 2026Review
- The regulatory mechanisms and clinical translation potential of RNA-binding protein RALY in tumors.Frontiers in oncology · 2026Review
- A Dual-Mechanism Targeted Cross-Convergence Prodrug Activation Strategy Enabled by Biological Stimulus Amplification toward Precision Cancer Therapy.Biomaterials research · 2026Article
- Bioactivity of mycosynthesized nanoparticles assists photothermal therapy of breast cancer cells.Apoptosis : an international journal on programmed cell death · 2025Article
- Multifunctional gold nanoparticles: bridging detection, diagnosis, and targeted therapy in cancer.Molecular cancer · 2025Review
- Nucleic acid drugs: recent progress and future perspectives.Signal transduction and targeted therapy · 2024Review
- Development and in vitro evaluation of a lignin-PLGA nanocarrier for florfenicol delivery.Veterinary research communications · 2024Article
- Cisplatin-encapsulated TRAIL-engineered exosomes from human chorion-derived MSCs for targeted cervical cancer therapy.Stem cell research & therapy · 2024Article
- Recent Advancements and Unexplored Biomedical Applications of Green Synthesized Ag and Au Nanoparticles: A Review.International journal of nanomedicine · 2024Review
- Exploring delivery systems for targeted nanotechnology-based gene therapy in the inner ear.Therapeutic delivery · 2024Review
- Approaches and applications in transdermal and transpulmonary gene drug delivery.Frontiers in bioengineering and biotechnology · 2024Review
- Advanced application of nanotechnology in active constituents of Traditional Chinese Medicines.Journal of nanobiotechnology · 2023Review
- Collagen Hydrogel Containing Polyethylenimine-Gold Nanoparticles for Drug Release and Enhanced Beating Properties of Engineered Cardiac Tissues.Advanced healthcare materials · 2023Article
- Optimization of CRISPR-Cas system for clinical cancer therapy.Bioengineering & translational medicine · 2023Review
- Gold Nanoparticles in Triple-Negative Breast Cancer Therapeutics.Current medicinal chemistry · 2023Review
- Next-generation engineered nanogold for multimodal cancer therapy and imaging: a clinical perspectives.Journal of nanobiotechnology · 2022Review
- Nano to rescue: repository of nanocarriers for targeted drug delivery to curb breast cancer.3 Biotech · 2022Review
- Article
- Targeting Engineered Nanoparticles for Breast Cancer Therapy.Pharmaceutics · 2021Review
- Smart Nanoparticles for Chemo-Based Combinational Therapy.Pharmaceutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundCancer is a complex heterogeneous disease to which singular modes of treatment mostly fail to produce a desired therapeutic efficacy. Targeting different cellular pathways using combinational therapies has been gaining popularity in cancer treatment, with the added benefit of reducing dosage and side effects.
methodsA gold nanoparticle-mediated drug delivery nanoplatform was developed for co-delivery of doxorubicin and polo-like kinase 1 (PLK1) siRNA. Gold nanoparticles were coated with polyethyleneimine to facilitate assembly of PLK1 on the surface. Doxorubicin was loaded on nanoparticles through a pH-sensitive linker with a thiol group at one terminal end for controlled release.
resultsThe therapeutic efficiency of this co-delivery system was evaluated in 2D and 3D cultured systems. The reduced IC
conclusionThis study may provide an adaptable, facile platform to investigate drug-siRNA combinations for cancer inhibition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.